<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Pak J Med Sci</journal-id><journal-id journal-id-type="iso-abbrev">Pak J Med Sci</journal-id><journal-title-group><journal-title>Pakistan Journal of Medical Sciences</journal-title></journal-title-group><issn pub-type="ppub">1682-024X</issn><issn pub-type="epub">1681-715X</issn><publisher><publisher-name>Professional Medical Publications</publisher-name><publisher-loc>Pakistan</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27882007</article-id><article-id pub-id-type="pmc">5103119</article-id><article-id pub-id-type="publisher-id">PJMS-32-1126</article-id><article-id pub-id-type="doi">10.12669/pjms.325.10640</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Therapeutic effects of sequential chemoradiotherapy with pemetrexed and cisplatin on locally advanced laryngeal cancer</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Tao</surname><given-names>Youmao</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ma</surname><given-names>Chong</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Yin</surname><given-names>Xiangdang</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Fang</surname><given-names>Xuedong</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Lixiu</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="corresp" rid="cor1"/></contrib></contrib-group><aff id="aff1"><label>1</label>Youmao Tao, China-Japan Union Hospital, Jilin University, Changchun 130033, China</aff><aff id="aff2"><label>2</label>Chong Ma, China-Japan Union Hospital, Jilin University, Changchun 130033, China</aff><aff id="aff3"><label>3</label>Xiangdang Yin, Jilin Cancer Hospital, Changchun 130001, China</aff><aff id="aff4"><label>4</label>Xuedong Fang, China-Japan Union Hospital, Jilin University, Changchun 130033, China</aff><aff id="aff5"><label>5</label>Lixiu Liu, China-Japan Union Hospital, Jilin University, Changchun 130033, China</aff><author-notes><corresp id="cor1">
Correspondence: Lixiu Liu, China-Japan Union Hospital, Jilin University, Changchun 130033, China. Email: <email xlink:href="liulixiucjuh@sina.com">liulixiucjuh@sina.com</email></corresp></author-notes><pub-date pub-type="ppub"><season>Sep-Oct</season><year>2016</year></pub-date><volume>32</volume><issue>5</issue><fpage>1126</fpage><lpage>1130</lpage><history><date date-type="received"><day>24</day><month>5</month><year>2016</year></date><date date-type="accepted"><day>05</day><month>8</month><year>2016</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; Pakistan Journal of Medical Sciences</copyright-statement><copyright-year>2016</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0"><license-p><!--CREATIVE COMMONS-->This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0">http://creativecommons.org/licenses/by/3.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec id="st1"><title>Objective:</title><p>To explore the therapeutic effects of sequential chemoradiotherapy with pemetrexed and cisplatin on locally advanced laryngeal cancer (LALC).</p></sec><sec id="st2"><title>Methods:</title><p>Fifty LALC patients who were treated in our hospital between January 2010 and January 2012 were selected and randomly divided into an observation group and a control group (n=25). The two groups were given conventional radiotherapy in the same manner, before which two cycles of chemotherapy were performed. The observation group intravenously infused with 500 mg/m<sup>2</sup> pemetrexed on d1 and 25 mg/m<sup>2</sup> cisplatin on d1-3, with 28 days as a cycle. The control group was intravenously infused with 25 mg/m<sup>2</sup> cisplatin on d1-3 and 400 mg/m<sup>2</sup> fluorouracil, with 28 days as a cycle. The short-term effects and adverse reactions of both groups were observed after treatment, and their survival was observed by follow-up for five years.</p></sec><sec id="st3"><title>Results:</title><p>The response rate was 84% (21/25) in the observation group and 64% (16/25) in the control group, between which the difference was statistically significant (P&#x0003c;0.05). The differences in the incidence rates of short-term adverse reactions such as grade III-IV gastrointestinal reactions and bone marrow suppression were not statistically significant between PC regimen (pemetrexed combined with cisplatin) and PF regimen (cisplatin combined with fluorouracil) (P&#x0003e;0.05). The incidence of long-term adverse reactions such as grade III-IV laryngeal edemas, laryngeal cartilage inflammation and laryngeal cartilage necrosis showed no significant differences between the two groups (P&#x0003e;0.05). The median survival was 3.3 years after PC chemotherapy and 2.8 years after PF chemotherapy, between which the difference was not statistically significant (P&#x0003e;0.05). The levels of serum tumor markers significantly decreased after PC and PF treatments compared with those before (P&#x0003c;0.05).</p></sec><sec id="st4"><title>Conclusion:</title><p>Combining PC chemotherapy with radiotherapy has satisfactory short-term therapeutic effects on LALC, and the resulting adverse effects can be tolerated. Therefore, this strategy is worthy of promotion and application in clinical practice.</p></sec></abstract><kwd-group><title>KEY WORDS</title><kwd>Laryngeal cancer</kwd><kwd>Pemetrexed</kwd><kwd>Cisplatin</kwd><kwd>Chemoradiotherapy</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-1"><title>INTRODUCTION</title><p>Laryngeal cancer is a common type of malignant tumor. Surgical treatment may be effective for early laryngeal cancer, which, however, is often difficult to achieve the desired results in patients with locally advanced laryngeal carcinoma (LALC). Concurrent chemoradiotherapy is a primary method of treatment for LALC,<xref rid="ref1" ref-type="bibr">1</xref> with 5-year overall survival rates of 10% to 45%. The standard chemotherapy regimen is cisplatin combined with fluorouracil (PF regimen).<xref rid="ref2" ref-type="bibr">2</xref> The 50 LALC patients who were treated in our hospital between January 2010 and January 2012 received PC regimen (pemetrexed combined with cisplatin) and PF regimen (cisplatin combined with fluorouracil), and the therapeutic effects and adverse reactions were compared.</p></sec><sec sec-type="methods" id="sec1-2"><title>METHODS</title><sec id="sec2-1"><title>Baseline clinical data</title><p>Fifty LALC patients who were treated in our hospital between January 2010 and January 2012 were selected. This study was approved by the ethics committee of our hospital, and written consent was obtained from all patients. They all received full physical examinations, routine blood test, clinical biochemical examination, frontal chest radiography, laryngoscopy and larynx MRI before treatment, with expected survival of over three months. They were all diagnosed as laryngeal squamous cell carcinoma by biopsy and pathological examination. The scores of systemic performance of the patients were 0-2 points. No abnormalities were observed in hepatic and renal functions or electrocardiogram before chemotherapy. There was no serious laryngostasis, and chemotherapy contraindications were excluded. The patients were randomly divided into an observation group and a control group (n=25). The observation group had 20 males and 5 females, aged between 34 and 77 (56.3 &#x000b1; 2.1) years old. Tumor stages and metastasis: 15 cases of T3, 10 cases of T4, 9 cases of N1, 12 cases of N2 and 4 cases of N3. Tumor locations: 12 cases of glottic cancer, 8 cases of supraglottic cancer and 5 cases of subglottic cancer. There were 19 males and 6 females in the control group, aged between 33 and 76 (54.6 &#x000b1; 3.2) years old. Tumor stages and metastasis: 14 cases of T3, 11 cases of T4, 8 cases of N1, 12 cases of N2 and 5 cases of N3. Tumor locations: 11 cases of glottic cancer, 9 cases of supraglottic cancer and 5 cases of subglottic cancer. The two groups had similar baseline clinical data (P&#x0003e;0.05).</p></sec><sec id="sec2-2"><title>Chemotherapy</title><p>The observation group received PC chemotherapy regimen: 500 mg/m<sup>2</sup> pemetrexed was intravenously infused for on d1 for over a half hour and 25 mg/m<sup>2</sup> cisplatin on d1-3, with 28 days as a cycle; pretreatment should be conducted with dexamethasone before using pemetrexed. The control group was intravenously infused with 25 mg/m<sup>2</sup> cisplatin on d1-3 and 400 mg/m<sup>2</sup> fluorouracil on d1-3, with 28 days as a cycle. During chemotherapy, the patients were subjected to fluid infusion as well as diuretic and antiemetic treatments. Radiotherapy was performed after two cycles of chemotherapy.</p></sec><sec id="sec2-3"><title>Radiotherapy</title><p>All patients received radiotherapy using Elekta precise dual-photon linear accelerator, covering primary lesions and the draining areas of lymph nodes. With CT for imitative positioning, the primary lesions and lymph node metastasis were outlined for digital reconstructed radiography (DRR). The multi-leaf collimator technology was used to directly sketch the irradiation range on DRR. A 6 MV photon line was selected, and electron beam irradiation with appropriate energy was applied on the posterior region of neck. Its radiation dose was Dt60-70 Gy/6-7 weeks (2.0 Gy/d, 5 times a week),<xref rid="ref3" ref-type="bibr">3</xref> and the spinal cord dose was less than 40 Gy. The patients who could receive surgery after radiotherapy for N2 or above lymph node metastasis were subjected to cervical lymph node dissection.</p></sec><sec id="sec2-4"><title>Observation indices and criteria for therapeutic effects</title><p>Laryngeal MRI and electronic laryngoscopy were reexamined one month after treatment to observe the short-term therapeutic effects.<xref rid="ref4" ref-type="bibr">4</xref> Complete remission (CR): Tumor disappears completely in longer than one month; partial response (PR): the product of the maximum diameter and the maximum perpendicular diameter of the tumor is reduced by over 50% in more than one month; stable: the product is reduced by no less than 50% and increased by no more than 25% in longer than one month; disease progression: the product exceeds 25%, or the patient dies. Response rate (RR) = CR + PR. Survival of the two groups was observed by follow-up for five years, and their adverse reactions were evaluated using the national cancer institute-adverse events commonly using terms.</p></sec><sec id="sec2-5"><title>Detection of serum tumor markers</title><p>Blood samples of the two groups were retained to detect tumor markers using chemiluminescence assay, including cytokeratin 19 fragment (CYFR21-1), carbohydrate antigen 19-9 (CA19-9), carcinoembryonic antigen (CEA) and squamous cell carcinoma-associated antigen (SCCAg).</p></sec><sec id="sec2-6"><title>Statistical analysis</title><p>All data were analyzed by SPSS19.0. The categorical data were expressed as ($$$$ &#x000b1;s) and compared by t test. The numerical data were expressed as relative numbers and compared with &#x003c7;<sup>2</sup> test. P&#x0003c;0.05 was considered statistically significant.</p></sec></sec><sec sec-type="results" id="sec1-3"><title>RESULTS</title><sec id="sec2-7"><title>Short-term therapeutic effects</title><p>RR was 84% (21/25) in the observation group and 64% (16/25) in the control group, between which the difference was statistically significant (&#x003c7;<sup>2</sup>=5.185, P&#x0003c;0.05) (<xref ref-type="table" rid="T1">Table-I</xref>).</p><table-wrap id="T1" position="float"><label>Table-I</label><caption><p>Short-term therapeutic effects (case).</p></caption><table frame="hsides" rules="groups" width="100%"><thead><tr><th align="left" rowspan="1" colspan="1"><italic>Group</italic></th><th align="left" rowspan="1" colspan="1"><italic>CR</italic></th><th align="left" rowspan="1" colspan="1"><italic>PR</italic></th><th align="left" rowspan="1" colspan="1"><italic>SD</italic></th><th align="left" rowspan="1" colspan="1"><italic>PD</italic></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Observation</td><td align="left" rowspan="1" colspan="1">15</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">Control</td><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">2</td></tr></tbody></table></table-wrap></sec><sec id="sec2-8"><title>Short-term adverse reactions</title><p>For observation and control groups, the incidence of grade III-IV gastrointestinal reactions and bone marrow suppression were 12% (3/25) and 20% (5/25) respectively, those of grade III-IV liver dysfunction were 12% (3/25) and 12% (3/25) respectively, those of grade III-IV kidney dysfunction were 16% (4/25) and 24% (6/25) respectively, and those of grade III-IV laryngeal reactions were 16% (4/25) and 24% (6/25) respectively. The differences in the incidence rates of short-term adverse reactions were not statistically significant between the two groups (&#x003c7;<sup>2</sup>=1.195, 1.315, 0.592, 1.118, 0.632, P&#x0003e;0.05) (<xref ref-type="table" rid="T2">Table-II</xref>).</p><table-wrap id="T2" position="float"><label>Table-II</label><caption><p>Short-term adverse reactions (case).</p></caption><table frame="hsides" rules="groups" width="100%"><thead><tr><th align="left" rowspan="1" colspan="1"><italic>Group</italic></th><th align="left" colspan="4" rowspan="1"><italic>Gastrointestinal reactions</italic></th><th align="left" colspan="4" rowspan="1"><italic>Bone marrow suppression</italic></th><th align="left" colspan="4" rowspan="1"><italic>Liver dysfunction</italic></th><th align="left" colspan="4" rowspan="1"><italic>Kidney dysfunction</italic></th><th align="left" colspan="4" rowspan="1"><italic>Laryngeal reactions</italic></th></tr><tr><th align="center" colspan="21" rowspan="1"><hr/></th></tr><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"><italic>I</italic></th><th align="left" rowspan="1" colspan="1"><italic>II</italic></th><th align="left" rowspan="1" colspan="1"><italic>III</italic></th><th align="left" rowspan="1" colspan="1"><italic>IV</italic></th><th align="left" rowspan="1" colspan="1"><italic>I</italic></th><th align="left" rowspan="1" colspan="1"><italic>II</italic></th><th align="left" rowspan="1" colspan="1"><italic>III</italic></th><th align="left" rowspan="1" colspan="1"><italic>IV</italic></th><th align="left" rowspan="1" colspan="1"><italic>I</italic></th><th align="left" rowspan="1" colspan="1"><italic>II</italic></th><th align="left" rowspan="1" colspan="1"><italic>III</italic></th><th align="left" rowspan="1" colspan="1"><italic>IV</italic></th><th align="left" rowspan="1" colspan="1"><italic>I</italic></th><th align="left" rowspan="1" colspan="1"><italic>II</italic></th><th align="left" rowspan="1" colspan="1"><italic>III</italic></th><th align="left" rowspan="1" colspan="1"><italic>IV</italic></th><th align="left" rowspan="1" colspan="1"><italic>I</italic></th><th align="left" rowspan="1" colspan="1"><italic>II</italic></th><th align="left" rowspan="1" colspan="1"><italic>III</italic></th><th align="left" rowspan="1" colspan="1"><italic>IV</italic></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Observation</td><td align="left" rowspan="1" colspan="1">11</td><td align="left" rowspan="1" colspan="1">11</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">10</td><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1">13</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">11</td><td align="left" rowspan="1" colspan="1">10</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">13</td><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">Control</td><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">10</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1">11</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">14</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">10</td><td align="left" rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">2</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x003c7;<sup>2</sup></td><td align="center" colspan="4" rowspan="1">1.194</td><td align="center" colspan="4" rowspan="1">1.314</td><td align="center" colspan="4" rowspan="1">0.591</td><td align="center" colspan="4" rowspan="1">1.117</td><td align="center" colspan="4" rowspan="1">0.633</td></tr><tr><td align="left" rowspan="1" colspan="1">P</td><td align="center" colspan="4" rowspan="1">&#x0003e;0.05</td><td align="center" colspan="4" rowspan="1">&#x0003e;0.05</td><td align="center" colspan="4" rowspan="1">&#x0003e;0.05</td><td align="center" colspan="4" rowspan="1">&#x0003e;0.05</td><td align="center" colspan="4" rowspan="1">&#x0003e;0.05</td></tr></tbody></table></table-wrap></sec><sec id="sec2-9"><title>Long-term adverse reactions</title><p>For observation and control groups, the incidence of grade III-IV laryngeal edemas were 8% (2/25) and 12% (3/25) respectively, those of grade III-IV laryngeal cartilage inflammation were 16% (4/25) and 16% (4/25) respectively, and those of laryngeal cartilage necrosis were 16% (4/25) and 20% (5/25) respectively. The incidence rates of long-term adverse reactions showed no significant differences between the two groups (&#x003c7;<sup>2</sup>=1.150, 1.281, 0.804, P&#x0003e;0.05) (<xref ref-type="table" rid="T3">Table-III</xref>).</p><table-wrap id="T3" position="float"><label>Table-III</label><caption><p>Long-term adverse reactions (case).</p></caption><table frame="hsides" rules="groups" width="100%"><thead><tr><th align="left" rowspan="1" colspan="1"><italic>Group</italic></th><th align="center" colspan="4" rowspan="1"><italic>Laryngeal edema</italic></th><th align="center" colspan="4" rowspan="1"><italic>Laryngeal cartilage inflammation</italic></th><th align="center" colspan="4" rowspan="1"><italic>L</italic></th></tr><tr><th align="center" colspan="13" rowspan="1"><hr/></th></tr><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"><italic>I</italic></th><th align="left" rowspan="1" colspan="1"><italic>II</italic></th><th align="left" rowspan="1" colspan="1"><italic>III</italic></th><th align="left" rowspan="1" colspan="1"><italic>IV</italic></th><th align="left" rowspan="1" colspan="1"><italic>I</italic></th><th align="left" rowspan="1" colspan="1"><italic>II</italic></th><th align="left" rowspan="1" colspan="1"><italic>III</italic></th><th align="left" rowspan="1" colspan="1"><italic>IV</italic></th><th align="left" rowspan="1" colspan="1"><italic>I</italic></th><th align="left" rowspan="1" colspan="1"><italic>II</italic></th><th align="left" rowspan="1" colspan="1"><italic>III</italic></th><th align="left" rowspan="1" colspan="1"><italic>IV</italic></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Observation</td><td align="left" rowspan="1" colspan="1">13</td><td align="left" rowspan="1" colspan="1">10</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">11</td><td align="left" rowspan="1" colspan="1">10</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">Control</td><td align="left" rowspan="1" colspan="1">10</td><td align="left" rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">11</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x003c7;<sup>2</sup></td><td align="center" colspan="4" rowspan="1">1.151</td><td align="center" colspan="4" rowspan="1">1.284</td><td align="center" colspan="4" rowspan="1">0.803</td></tr><tr><td align="left" rowspan="1" colspan="1">P</td><td align="center" colspan="4" rowspan="1">&#x0003e;0.05</td><td align="center" colspan="4" rowspan="1">&#x0003e;0.05</td><td align="center" colspan="4" rowspan="1">&#x0003e;0.05</td></tr></tbody></table></table-wrap></sec><sec id="sec2-10"><title>Survival times</title><p>During the 5-year follow-up, four cases in the observation group and three cases in the control group were lost to follow up. Three cases in the observation group and four cases in the control group received cervical lymph node dissection after treatment. After the patients who lost contact were excluded, the 5-year survival rate of the remaining 43 patients was 32.55% (14/43). Such rate of the observation group (33.33% (7/21)) was similar to that of the control group (31.81% (7/22)) (P&#x0003e;0.05). The median survival of the 43 patients was 3.1 years [95% confidential interval (CI): 1.61-3.22]. Such time was 3.3 years [95%CI: 1.92-2.89] after PC chemotherapy and 2.8 years [95%CI: 1.54-3.17] after PF chemotherapy, between which the difference was not statistically significant (P&#x0003e;0.05) (<xref ref-type="fig" rid="F1">Fig.1</xref>).</p><fig id="F1" position="float"><label>Fig.1</label><caption><p>Kaplan-Meler survival curves.</p></caption><graphic xlink:href="PJMS-32-1126-g001"/></fig></sec><sec id="sec2-11"><title>Levels of serum tumor markers before and after chemotherapy</title><p>The levels of serum tumor markers (CYFR21-1, CA19-9, CEA, SCCAg) significantly decreased after PC and PF treatments compared with those before (P&#x0003c;0.05) (<xref ref-type="table" rid="T4">Table-IV</xref>).</p><table-wrap id="T4" position="float"><label>Table-IV</label><caption><p>Levels of serum tumor markers before and after chemotherapy.</p></caption><table frame="hsides" rules="groups" width="100%"><thead><tr><th align="left" rowspan="1" colspan="1"><italic>Serum tumor marker</italic></th><th align="center" colspan="2" rowspan="1"><italic>Observation group (n=25)</italic></th><th align="center" rowspan="1" colspan="1"><italic>P</italic></th><th align="center" colspan="2" rowspan="1"><italic>Control group (n=25)</italic></th><th align="center" rowspan="1" colspan="1"><italic>P</italic></th></tr><tr><th align="center" colspan="7" rowspan="1"><hr/></th></tr><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"><italic>Before treatment</italic></th><th align="left" rowspan="1" colspan="1"><italic>After treatment</italic></th><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"><italic>Before treatment</italic></th><th align="left" rowspan="1" colspan="1"><italic>After treatment</italic></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">CYFR21-1 (ng/ml)</td><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;4.77&#x000b1;1.02</td><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;2.03&#x000b1;0.55</td><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x0003c;0.05</td><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;4.87&#x000b1;1.03</td><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;2.01&#x000b1;0.53</td><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x0003c;0.05</td></tr><tr><td align="left" rowspan="1" colspan="1">CA19-9 (U/ml)</td><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;45.24&#x000b1;7.47</td><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;21.13&#x000b1;3.57</td><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x0003c;0.05</td><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;45.37&#x000b1;7.22</td><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;22.04&#x000b1;3.12</td><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x0003c;0.05</td></tr><tr><td align="left" rowspan="1" colspan="1">CEA (ng/ml)</td><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;8.77&#x000b1;2.34</td><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;3.34&#x000b1;1.01</td><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x0003c;0.05</td><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;8.97&#x000b1;2.04</td><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;3.17&#x000b1;1.04</td><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x0003c;0.05</td></tr><tr><td align="left" rowspan="1" colspan="1">SCCAg (ng/ml)</td><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;2.09&#x000b1;1.11</td><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;1.14&#x000b1;0.44</td><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x0003c;0.05</td><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;2.15&#x000b1;0.77</td><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;1.13&#x000b1;0.42</td><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x0003c;0.05</td></tr></tbody></table></table-wrap></sec></sec><sec sec-type="discussion" id="sec1-4"><title>DISCUSSION</title><p>The incidence of LALC is increasingly high in clinical practice, and the number of LALC patients accounts for about 70% of the total number of laryngeal cancer cases.<xref rid="ref5" ref-type="bibr">5</xref> Laryngeal cancer is more sensitive to radiotherapy which can maintain the normal structure and vocal function of patients to improve their quality of life.<xref rid="ref6" ref-type="bibr">6</xref> In case of recurrence after treatment, partial laryngectomy or total laryngectomy can be used, but the methods are not effective for locally advanced laryngeal squamous cell carcinoma.<xref rid="ref7" ref-type="bibr">7</xref>,<xref rid="ref8" ref-type="bibr">8</xref> Chemotherapy is still one of the main methods, which can elevate the retention rate of the larynx. Previous randomized experimental studies have shown that concurrent chemoradiotherapy was superior to single radiotherapy and postoperative adjuvant radiotherapy, but the side effects should not be neglected.<xref rid="ref9" ref-type="bibr">9</xref></p><p>Cisplatin, as the most commonly used metal platinum complex, is a cell-cycle non-specific anticancer drug. With activities for both aerobic and anaerobic cells, it can enhance the sensitivity to radiotherapy. Cisplatin exhibits antitumor activity mainly through the central axis in the structure, cross-links with DNA or form cross-linking between DNA and protein, so as to inhibit DNA replication, transcription and proliferation of tumor cells.</p><p>PF regimen is common in clinical practice for the chemotherapy of head and neck tumors, with the efficiency of about 40%. This regimen enables patients to maintain normal vocal cord and vocal function as well as to improve their quality of life, but fails to prolong the overall survival. Pemetrexed is a plant-derived anticancer drug acting on the M phase, which prevents the recombination of microtubules related to mitosis and other important cellular functions and induces apoptosis by promoting them to aggregate into stable forms and inhibiting their deaggregation. As evidenced by phase II clinical experiments for head and neck squamous cell carcinoma, pemetrexed had high efficiency and tolerance to toxic and side effects. In addition, pemetrexed can evidently augment the sensitivity to radiotherapy, which has been widely used in the treatment of head and neck tumors.<xref rid="ref10" ref-type="bibr">10</xref>-<xref rid="ref12" ref-type="bibr">12</xref> PC regimen has also become a main way of chemotherapy for head and neck tumors,<xref rid="ref13" ref-type="bibr">13</xref> but the superiority of its long-term efficacy to that of PF chemotherapy has not been proved hitherto.</p><p>Laryngeal cancer may be diagnosed by tumor histocytological or pathological examination. Tumor markers, as an auxiliary examination means of laryngeal cancer diagnosis, play vital roles in laboratory tests and are usually abundant in tumor tissues and serum. Their changes are often of great significance to tumor classification, diagnosis, treatment and prognosis. In the follow-up after treatment, some tumor markers can be used as indices for evaluating the cancer status. During periodic follow-up, tumor recurrence and metastasis can be detected earlier through the detection of tumor markers. CEA is a specific antigen of human embryo, the dynamic changes of which are closely related to tumor therapeutic effects, progression and metastasis. CYFR21-1, CA19-9 and SCCAg are significantly correlated with tumor stage and histological type.<xref rid="ref14" ref-type="bibr">14</xref>-<xref rid="ref16" ref-type="bibr">16</xref> In this study, after treatment, the CYFR21-1, CA19-9, CEA and SCCAg levels significantly reduced in both groups compared with those before treatment.</p><p>The short-term effects of the observation group significantly surpassed those of the control group, with a significantly higher RR. As to the 5-year survival rate, although there was no significant difference between the groups, the median survival of the observation group was longer. Nevertheless, the sample size in this study is small, so the optimum method of administration and dosage of concurrent PC chemotherapy and radiotherapy for LALC patients still need to be further confirmed by multicenter clinical trials with larger sample sizes.</p></sec></body><back><fn-group><fn fn-type="financial-disclosure"><p><bold><italic>Grant Support &#x00026; Financial Disclosures:</italic></bold> None.</p></fn></fn-group><sec id="sec1-5"><title/><sec id="sec2-12"><title>Authors&#x02019; Contributions</title><p><bold>YT &#x00026; LL</bold> conceived, designed and did statistical analysis &#x00026; editing of manuscript.</p><p><bold>CM, XY &#x00026; XF</bold> did data collection and manuscript writing.</p><p><bold>LL</bold> did review and final approval of manuscript.</p></sec></sec><ref-list><title>REFERENCES</title><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Osborn</surname><given-names>HA</given-names></name><name><surname>Hu</surname><given-names>A</given-names></name><name><surname>Venkatesan</surname><given-names>V</given-names></name><name><surname>Nichols</surname><given-names>A</given-names></name><name><surname>Franklin</surname><given-names>JH</given-names></name><name><surname>Yoo</surname><given-names>JH</given-names></name><etal/></person-group><article-title>Comparison of endoscopic laser resection versus radiation therapy for the treatment of early glottic carcinoma</article-title><source>J Otolaryngol Head Neck Surg</source><year>2011</year><volume>40</volume><issue>3</issue><fpage>200</fpage><lpage>204</lpage><comment>doi:10.2310/7070.2011.100239</comment><pub-id pub-id-type="pmid">21518640</pub-id></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kerr</surname><given-names>P</given-names></name><name><surname>Mark Taylor</surname><given-names>S</given-names></name><name><surname>Rigby</surname><given-names>M</given-names></name><name><surname>Myers</surname><given-names>C</given-names></name><name><surname>Osborn</surname><given-names>H</given-names></name><name><surname>Lambert</surname><given-names>P</given-names></name><etal/></person-group><article-title>Oncologic and voice outcomes after treatment of early glottic cancer:transoral laser microsurgery versus radiotherapy</article-title><source>J Otolaryngol Head Neck Surg</source><year>2012</year><volume>41</volume><issue>6</issue><fpage>381</fpage><lpage>388</lpage><comment>doi:10.2310/7070.2012.00043</comment><pub-id pub-id-type="pmid">23700582</pub-id></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tong</surname><given-names>CC</given-names></name><name><surname>Au</surname><given-names>KH</given-names></name><name><surname>Ngan</surname><given-names>RK</given-names></name><name><surname>Cheung</surname><given-names>FY</given-names></name><name><surname>Chow</surname><given-names>SM</given-names></name><name><surname>Fu</surname><given-names>YT</given-names></name><etal/></person-group><article-title>Definitive radiotherapy for early stage glottic cancer by 6 MV photons</article-title><source>Head Neck Oncol</source><year>2012</year><volume>4</volume><fpage>23</fpage><comment>doi:10.1186/1758-3284-4-23</comment><pub-id pub-id-type="pmid">22607730</pub-id></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paluszczak</surname><given-names>J</given-names></name><name><surname>Misiak</surname><given-names>P</given-names></name><name><surname>Wierzbicka</surname><given-names>M</given-names></name><name><surname>Wozniak</surname><given-names>A</given-names></name><name><surname>Baer-Dubowska</surname><given-names>W</given-names></name></person-group><article-title>Frequent hypermethylation of DAPK, RARbeta, MGMT, RASSF1A and FHIT in laryngeal squamous cell carcinomas and adjacent normal mucosa</article-title><source>Oral Oncol</source><year>2011</year><volume>47</volume><issue>2</issue><fpage>104</fpage><lpage>107</lpage><comment>doi:10.1016/j.oraloncology.2010.11.006</comment><pub-id pub-id-type="pmid">21147548</pub-id></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murai</surname><given-names>R</given-names></name><name><surname>Yoshida</surname><given-names>Y</given-names></name><name><surname>Muraguchi</surname><given-names>T</given-names></name><name><surname>Nishimoto</surname><given-names>E</given-names></name><name><surname>Morioka</surname><given-names>Y</given-names></name><name><surname>Kitayama</surname><given-names>H</given-names></name><etal/></person-group><article-title>A novel screen using the Reck tumor suppressor gene promoter detects both conventional and metastasis-suppressing anticancer drugs</article-title><source>Oncotarget</source><year>2010</year><volume>1</volume><issue>4</issue><fpage>252</fpage><lpage>264</lpage><pub-id pub-id-type="pmid">21304177</pub-id></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Feng</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>T</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Ren</surname><given-names>J</given-names></name><etal/></person-group><article-title>Long intergenic noncoding RNA HOTAIR is overexpressed and regulates PTEN methylation in laryngeal squamous cell carcinoma</article-title><source>Am J Pathol</source><year>2013</year><volume>182</volume><issue>1</issue><fpage>64</fpage><lpage>70</lpage><comment>doi:10.1016/j.ajpath.2012.08.042</comment><pub-id pub-id-type="pmid">23141928</pub-id></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Minor</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Song</surname><given-names>J</given-names></name><name><surname>Jimeno</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>XJ</given-names></name><etal/></person-group><article-title>Methylation of microRNA-9 is a specific and sensitive biomarker for oral and oropharyngeal squamous cell carcinomas</article-title><source>Oral Oncol</source><year>2012</year><volume>48</volume><issue>1</issue><fpage>73</fpage><lpage>78</lpage><comment>doi:10.1016/j.oraloncology.2011.11.006</comment><pub-id pub-id-type="pmid">22133638</pub-id></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hakeem</surname><given-names>AH</given-names></name><name><surname>Tubachi</surname><given-names>J</given-names></name><name><surname>Pradhan</surname><given-names>SA</given-names></name></person-group><article-title>Significance of anterior commissure involvement in early glottic squamous cell carcinoma treated with trans-oral CO<sub>2</sub>laser microsurgery</article-title><source>Laryngoscope</source><year>2013</year><volume>123</volume><issue>8</issue><fpage>1912</fpage><lpage>1917</lpage><comment>doi:10.1002/lary.24012</comment><pub-id pub-id-type="pmid">23606304</pub-id></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spielmann</surname><given-names>PM</given-names></name><name><surname>Majumdar</surname><given-names>S</given-names></name><name><surname>Morton</surname><given-names>RP</given-names></name></person-group><article-title>Quality of life and functional outcomes in the management of early glottic carcinoma:a systematic review of studies comparing radiotherapy and transoral laser microsurgery</article-title><source>Clin Otolaryngol</source><year>2010</year><volume>35</volume><issue>5</issue><fpage>373</fpage><lpage>382</lpage><comment>doi:10.1111/j.1749-4486.2010.02191.x</comment><pub-id pub-id-type="pmid">21108747</pub-id></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>TS</given-names></name><name><surname>Li</surname><given-names>FY</given-names></name><name><surname>Wang</surname><given-names>SQ</given-names></name></person-group><article-title>Treatment of advanced non-small cell lung cancer with docetaxel in combination with tegafur, gimeracil and oteracil porassium capsules</article-title><source>Military Med J South China</source><year>2011</year><issue>03</issue><fpage>261</fpage><lpage>262</lpage></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Mamgani</surname><given-names>A</given-names></name><name><surname>van Rooij</surname><given-names>PH</given-names></name><name><surname>Mehilal</surname><given-names>R</given-names></name><name><surname>Verduijn</surname><given-names>GM</given-names></name><name><surname>Tans</surname><given-names>L</given-names></name><name><surname>Kwa</surname><given-names>SL</given-names></name></person-group><article-title>Radiotherapy for T1a glottic cancer:the influence of smoking cessation and fractionation schedule of radiotherapy</article-title><source>Eur Arch Otorhinolaryngol</source><year>2014</year><volume>271</volume><issue>1</issue><fpage>125</fpage><lpage>132</lpage><comment>doi:10.1007/s00405-013-2608-8</comment><pub-id pub-id-type="pmid">23797970</pub-id></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>TG</given-names></name><name><surname>Ahn</surname><given-names>YC</given-names></name><name><surname>Nam</surname><given-names>HR</given-names></name><name><surname>Chung</surname><given-names>MK</given-names></name><name><surname>Jeong</surname><given-names>HS</given-names></name><name><surname>Son</surname><given-names>YI</given-names></name><etal/></person-group><article-title>Definitive radiation therapy for early glottic cancer:experience of two fractionation schedules</article-title><source>Clin Exp Otorhinolaryngol</source><year>2012</year><volume>5</volume><issue>2</issue><fpage>94</fpage><lpage>100</lpage><comment>doi:10.3342/ceo.2012.5.2.94</comment><pub-id pub-id-type="pmid">22737290</pub-id></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>WX</given-names></name></person-group><article-title>Thyroid metastasis of occult breast cancer:Case report and literature review</article-title><source>Military Med J South China</source><year>2012</year><issue>06</issue><fpage>609</fpage></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanada</surname><given-names>S</given-names></name><name><surname>Nishiyama</surname><given-names>N</given-names></name><name><surname>Mizuguchi</surname><given-names>S</given-names></name><name><surname>Yamano</surname><given-names>S</given-names></name><name><surname>Kakehashi</surname><given-names>A</given-names></name><name><surname>Wei</surname><given-names>M</given-names></name><etal/></person-group><article-title>Clinicopathological significance of combined analysis of cytokeratin19 expression and preoperative serum CYFRA21-1 levels in human lung squamous cell carcinoma</article-title><source>Osaka City Med J</source><year>2013</year><volume>59</volume><issue>1</issue><fpage>35</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">23909079</pub-id></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheng</surname><given-names>X</given-names></name><name><surname>Du</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Lu</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Clinical value of serum HMGB1 levels in early detection of recurrent squamous cell carcinoma of uterine cervix:comparison with serum SCCA, CYFRA21-1, and CEA levels</article-title><source>Croat Med J</source><year>2009</year><volume>50</volume><issue>5</issue><fpage>455</fpage><lpage>464</lpage><comment>doi:10.3325/cmj.2009.50.455</comment><pub-id pub-id-type="pmid">19839069</pub-id></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Molina</surname><given-names>R</given-names></name><name><surname>Filella</surname><given-names>X</given-names></name><name><surname>Auge</surname><given-names>JM</given-names></name><name><surname>Fuentes</surname><given-names>R</given-names></name><name><surname>Bover</surname><given-names>I</given-names></name><name><surname>Rifa</surname><given-names>J</given-names></name><etal/></person-group><article-title>Tumor markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in patients with non-small cell lung cancer as an aid in histological diagnosis and prognosis. Comparison with the main clinical and pathological prognostic factors</article-title><source>Tumour Biol</source><year>2003</year><volume>24</volume><issue>4</issue><fpage>209</fpage><lpage>218</lpage><comment>doi:10.1016/S0169-5002(00)80662-5</comment><pub-id pub-id-type="pmid">14654716</pub-id></element-citation></ref></ref-list></back></article>